Celon Pharma SA(DE:8RP)
€3.34+0.01 (+0.45%)
DE:8RP
Celon Pharma SA financials statements
€3.34
At close:+0.01 (+0.45%)
Celon Pharma SA (8RP) Ratios
2 Followers
Celon Pharma SA Ratios
DE:8RP's free cash flow for Q3 2026 was zł-32.41M. For the 2026 fiscal year, DE:8RP's free cash flow was decreased by zł-41.45M and operating cash flow was zł9.04M. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.62 | 1.84 | 2.20 | 2.04 | 3.23 |
| Quick Ratio | 1.20 | 1.51 | 1.89 | 1.71 | 2.96 |
| Cash Ratio | 0.31 | 0.10 | 0.37 | 0.71 | 1.71 |
| Solvency Ratio | -0.44 | 0.18 | 0.18 | 0.04 | 0.19 |
| Operating Cash Flow Ratio | 0.38 | -0.13 | -0.10 | -0.04 | 0.51 |
| Short-Term Operating Cash Flow Coverage | 14.79 | -7.41 | -0.65 | 0.00 | 6.70 |
| Net Current Asset Value | zł 27.80M | zł 61.84M | zł 66.00M | zł 108.29M | zł 125.56M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.04 | 0.03 | 0.04 | 0.04 | 0.02 |
| Debt-to-Equity Ratio | 0.05 | 0.04 | 0.06 | 0.06 | 0.03 |
| Debt-to-Capital Ratio | 0.05 | 0.04 | 0.05 | 0.05 | 0.03 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.26 | 1.22 | 1.28 | 1.27 | 1.28 |
| Debt Service Coverage Ratio | -9.62 | 4.97 | 1.59 | 3.88 | 3.86 |
| Interest Coverage Ratio | -35.54 | -14.89 | -10.22 | -41.75 | -6.73 |
| Debt to Market Cap | 0.00 | 0.00 | 0.02 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.38 | 0.37 | 0.55 | 0.56 | 0.35 |
| Net Debt to EBITDA | 0.04 | 0.58 | -0.21 | -6.02 | -4.78 |
| Profitability Margins | |||||
| Gross Profit Margin | -18.82% | 64.23% | 68.76% | 58.95% | 68.53% |
| EBIT Margin | -27.06% | -20.89% | -8.09% | -21.48% | -6.90% |
| EBITDA Margin | -4.99% | 8.47% | 15.29% | 5.76% | 14.18% |
| Operating Profit Margin | -27.06% | -20.84% | -12.73% | -43.08% | -5.33% |
| Pretax Profit Margin | -28.11% | -22.29% | -9.33% | -22.51% | -7.69% |
| Net Profit Margin | -37.83% | -19.50% | -13.15% | -24.26% | -5.92% |
| Continuous Operations Profit Margin | -37.83% | -19.50% | -13.15% | -24.26% | -5.92% |
| Net Income Per EBT | 134.59% | 87.50% | 140.85% | 107.77% | 76.93% |
| EBT Per EBIT | 103.88% | 106.95% | 73.30% | 52.24% | 144.33% |
| Return on Assets (ROA) | -17.35% | -6.33% | -4.94% | -6.45% | -1.64% |
| Return on Equity (ROE) | -21.85% | -7.74% | -6.31% | -8.19% | -2.10% |
| Return on Capital Employed (ROCE) | -14.40% | -8.06% | -5.64% | -14.16% | -1.68% |
| Return on Invested Capital (ROIC) | -14.09% | -6.92% | -5.42% | -13.63% | -1.27% |
| Return on Tangible Assets | -17.96% | -6.43% | -5.07% | -6.70% | -1.71% |
| Earnings Yield | -7.24% | -2.48% | -3.50% | -5.49% | -0.75% |
| Efficiency Ratios | |||||
| Receivables Turnover | 4.02 | 4.01 | 4.43 | 4.80 | 7.20 |
| Payables Turnover | 14.61 | 4.03 | 6.36 | 3.80 | 5.20 |
| Inventory Turnover | 9.55 | 2.16 | 2.53 | 1.73 | 2.64 |
| Fixed Asset Turnover | 0.69 | 0.57 | 0.64 | 0.53 | 0.60 |
| Asset Turnover | 0.46 | 0.32 | 0.38 | 0.27 | 0.28 |
| Working Capital Turnover Ratio | 3.74 | 2.00 | 1.91 | 1.03 | 1.99 |
| Cash Conversion Cycle | 104.00 | 169.22 | 169.16 | 190.82 | 118.73 |
| Days of Sales Outstanding | 90.76 | 90.95 | 82.30 | 75.97 | 50.71 |
| Days of Inventory Outstanding | 38.23 | 168.85 | 144.24 | 210.81 | 138.23 |
| Days of Payables Outstanding | 24.99 | 90.58 | 57.38 | 95.96 | 70.21 |
| Operating Cycle | 128.99 | 259.80 | 226.55 | 286.78 | 188.95 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.44 | -0.22 | -0.16 | -0.09 | 0.94 |
| Free Cash Flow Per Share | -0.57 | -0.65 | -0.81 | -0.76 | 0.06 |
| Dividend Paid and CapEx Coverage Ratio | 0.44 | -0.42 | -0.22 | -0.10 | 0.99 |
| Capital Expenditure Coverage Ratio | 0.44 | -0.50 | -0.25 | -0.14 | 1.06 |
| Operating Cash Flow Coverage Ratio | 1.26 | -0.67 | -0.32 | -0.18 | 2.95 |
| Operating Cash Flow to Sales Ratio | 0.11 | -0.06 | -0.04 | -0.03 | 0.22 |
| Free Cash Flow Yield | -2.79% | -2.46% | -5.11% | -5.40% | 0.17% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -13.84 | -40.32 | -28.61 | -18.21 | -133.31 |
| Price-to-Sales (P/S) Ratio | 5.22 | 7.86 | 3.76 | 4.42 | 7.89 |
| Price-to-Book (P/B) Ratio | 3.02 | 3.12 | 1.81 | 1.49 | 2.79 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -35.85 | -40.70 | -19.57 | -18.53 | 595.13 |
| Price-to-Operating Cash Flow Ratio | 45.92 | -122.50 | -96.78 | -152.17 | 35.21 |
| Price-to-Earnings Growth (PEG) Ratio | -0.11 | -2.02 | 1.00 | -0.09 | -0.12 |
| Enterprise Value Multiple | -104.55 | 93.41 | 24.39 | 70.74 | 50.87 |
| Enterprise Value | 1.10B | 1.40B | 797.88M | 659.28M | 1.41B |
| EV to EBITDA | -104.55 | 93.41 | 24.39 | 70.74 | 50.87 |
| EV to Sales | 5.22 | 7.91 | 3.73 | 4.07 | 7.21 |
| EV to Free Cash Flow | -35.84 | -40.95 | -19.40 | -17.08 | 544.02 |
| EV to Operating Cash Flow | 45.91 | -123.26 | -95.97 | -140.24 | 32.18 |
| Tangible Book Value Per Share | 6.82 | 8.32 | 8.43 | 8.95 | 11.24 |
| Shareholders’ Equity Per Share | 6.74 | 8.48 | 8.73 | 9.40 | 11.87 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.35 | 0.13 | -0.41 | -0.08 | 0.23 |
| Revenue Per Share | 3.90 | 3.36 | 4.19 | 3.17 | 4.20 |
| Net Income Per Share | -1.47 | -0.66 | -0.55 | -0.77 | -0.25 |
| Tax Burden | 1.35 | 0.88 | 1.41 | 1.08 | 0.77 |
| Interest Burden | 1.04 | 1.07 | 1.15 | 1.05 | 1.11 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.25 |
| SG&A to Revenue | 0.08 | 0.14 | 0.00 | 0.00 | 0.19 |
| Stock-Based Compensation to Revenue | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 |
| Income Quality | -0.30 | 0.29 | 0.30 | 0.13 | -2.91 |
Currency in PLN

